Goldman Charge Curbs Enthusiasm for Market Risk

300 mg Seroquel Larger Cap Healthcare Stocks Holding Up Well The SEC charges against Goldman Sachs have taken the MO out of the market with speculative issues down considerably. As of midday trading the Dow is down 1.2%. NASDAQ down 1.5% and the S&P down 1.6%.Stocks are off their lows. Large Cap healthcare and biotech stocks were less […]

Continue Reading 0

Rayno Life Science Portfolio 2010: Biopharmaceuticals

buy provigil online ireland Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene Genzyme and Gilead all down. The IBB is flat for the year. […]

Continue Reading 0

Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera

http://wi-5.com/wp-cron.php?doing_wp_cron=1523525427.1319580078125000000000 Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is being added as a buy […]

Continue Reading 0

Immucor(BLUD) Profits Up but Stock Down 8 %

Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry  delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross margin was 69.2% compared to prior year quarter of 71.4%. Diluted earnings per share […]

Continue Reading 0

Gene Patent Ruling stalls Biotech Rally-Myriad (MYGN) down 4.9%

US Judge invalidates cancer gene patents Intellectual Property (IP) is the raw material for the creation of biotech companies. Without an invention covered by a robust patent portfolio, venture funding can be very difficult. Since the beginning of the “genomic age” in the late nineties the patenting of genetic materials and methods have gone through […]

Continue Reading 0

Market Reversal Today -Be Cautious

The market reversed today about 1:30p EDT as positive Bernanke chat yielded to Trichet and the Baklava Bailout. The NASDAQ Comp was up to the 2430 range then closed at 2397. The Rayno Life Science Index of 34 mid-cap biotechs was up 1.7% with 32 greens at 1:30p  then finished down 0.5% with only 8 […]

Continue Reading 0

2009-2010 Life Sciences Portfolio

The Raygent Model Portfolio was created in February 2009 and will be updated by the end of March 2010.The 14 month YTD performance is up 25%. New buys over past four months were Sequenom (SQNM) and SeraCare (SRLS). Currently under review are Immucor (BLUD) , MicroFluidics (MLFU) , Genomic Health (GHDH) and Genoptix (GXDX). Published […]

Continue Reading 0

Healthcare Stocks up-Market absorbs Reform

Healthcare and biotech stocks were up today as expected following passage of the historic reform bill. Although there is a considerable amount of work to be done in enabling the historic legislation, uncertainty has been removed and the market can play it out. Many analysts and economists previously have forecasted upside potential for pharmaceutical, biotechnology […]

Continue Reading 0

2010 Life Science Portfolio-Look at Immucor (BLUD)

We are currently rebalancing our 2010 Life Science Portfolio (See under “Articles” at top of WEB site). We are updating our Diagnostics and Genomics Model Portfolio as follows: Our winners for a 14 month period YTD are Abaxis (ABAX),Hologic (HOLX), Illumina(ILMN) and Inverness(IMA). All remain strong holds. Additional holds are GenProbe (GPRO) and Qiagen(QGEN).We are […]

Continue Reading 0

Sequenom (SQNM) Catching Bids at $5.75

Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three  day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of the Company to give a detailed financial outlook but that […]

Continue Reading 0